IR@PKUHSC  > 北京大学第一临床医学院  > 核医学科
学科主题核医学
核素示踪靶向肿瘤新生血管分子探针的研究进展
其他题名Progress and prospect of molecular probes of radionuclide tracing targeted tumor angiogenesis
王荣福
关键词肿瘤新生血管 异质性 早期诊断 个性化治疗 精氨酸-精氨酸-亮氨酸 Tumor Angiogenesis Heterogeneity Early Diagnosis Personalized Treatment Argi-nine-arginine-leucine
刊名国际放射医学核医学杂志
2015
DOI10.3760/cma.j.issn.1673-4114.2015.01.011
1页:50-54
文章类型Journal Article
摘要肿瘤是一种严重危害人类健康和生命的疾病,它的早期诊断和早期治疗可以明显延长患者的生存时间和提高患者的生活质量。目前,肿瘤靶向诊断和靶向治疗成为研究热点。靶向肿瘤新生血管的多肽精氨酸-精氨酸-亮氨酸(RRL)序列能够特异性靶向结合于肿瘤来源内皮细胞,国内学者证实了131I-RRL对肿瘤细胞的杀伤作用,以及99Tcm-RRL在不同肿瘤模型中的SPECT显像效果。国外学者已经将靶向肿瘤新生血管的小分子多肽精氨酸-甘氨酸-天冬氨酸用于临床前期阶段。 Tumor is hazard to human health and lives. Early diagnosis and treatment of tumor can obviously prolong patient survival time and improve the quality of life. At present, targeting diagnosis and therapy catch attention of researchers from all over the world. Peptide arginine-arginine-leucine (RRL) sequence is specific targeted to tumor-derived endothelial cell. Our team confirmed that the 131I-RRL had the effect of killing tumor cells, and 99Tcm-RRL could image tumors in different tumor models. Foreign scholars have already put the small molecules arginine-arginine-leucine targeting tumor angiogenesis in the preclinical stage.
语种中文
原文出处查看原文
Citation statistics
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/43089
Collection北京大学第一临床医学院_核医学科
作者单位北京大学第一医院核医学科,100034
Recommended Citation
GB/T 7714
王荣福. 核素示踪靶向肿瘤新生血管分子探针的研究进展[J]. 国际放射医学核医学杂志,2015(1):50-54.
APA 王荣福.(2015).核素示踪靶向肿瘤新生血管分子探针的研究进展.国际放射医学核医学杂志(1),50-54.
MLA 王荣福."核素示踪靶向肿瘤新生血管分子探针的研究进展".国际放射医学核医学杂志 .1(2015):50-54.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[王荣福]'s Articles
百度学术
百度学术Similar articles in
[王荣福]'s Articles
必应学术
必应学术Similar articles in
[王荣福]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.